Did you know?

TransCode Therapeutics has also granted underwriters of the offering a 45-day option to acquire another 2,339,200 shares. These will be priced the same as the shares included in the public stock ...Jul-08-21 06:34PM. TransCode Therapeutics, Inc. Announces Pricing of Initial Public Offering. (Business Wire) TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in ... A few examples include what has shares of Roblox (NYSE:RBLX), PTC Therapeutics (NASDAQ:PTCT) and TransCode Therapeutics (NASDAQ:RNAZ) stock moving today. You can catch up on all of this news at ...Stock Price Forecast The 1 analysts offering 12-month price forecasts for Transcode Therapeutics Inc have a median target of 3.00, with a high estimate of 3.00 and a low estimate of 3.00.BOSTON, Nov. 30, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has entered into a definitive securities purchase agreement for the purchase and sale of 5,000,000 shares of common stock at a purchase price of $0.242 per share of common ...Item 1. Description of Registrant’s Securities to be Registered. For a description of the common stock, $0.0001 par value per share, of TransCode Therapeutics, Inc., a Delaware corporation (the “Registrant”), to be registered hereunder, reference is made to the information set forth under the heading “Description of Capital Stock” in the Registrant’s …Complete TransCode Therapeutics Inc. stock information by Barron's. View real-time RNAZ stock price and news, along with industry-best analysis.TransCode Therapeutics stock is dropping alongside public offering plans.; The company hasn’t revealed the terms of the public offering just yet. That means traders still don’t know how many ...The shares of common stock described above were offered by the Company pursuant to a “shelf” registration statement on Form S-3 (File No. 333-268764) previously filed with the Securities and ...TransCode Therapeutics ( NASDAQ: RNAZ) said that it has entered into a definitive securities purchase agreement for the purchase and sale of 5,000,000 shares of common stock at a purchase price of ...--TransCode Therapeutics, Inc.,, an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the pricing of its underwritten public offering of an ...BOSTON, April 14, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to more effectively treating ...TransCode Therapeutics Announces Public Offering of Common Stock. October 26, 2023. PDF Version. BOSTON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the commencement of an ...26 thg 9, 2023 ... Use of technology ... TransCode Therapeutics (NASDAQ:RNAZ) stock has seen a wild 24 hours of trading as the Boston headquartered nano-cap drug ...TransCode is an RNA oncology company created on the belief that cancer can be more effectively treated using RNA therapeutics. The Company has created a platform of drug candidates designed to ...TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating …BOSTON, Oct. 27, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA ...Sep 25, 2023 · RNAZ stock soared on the possible implications of addressing brain tumors. Enlivening a soft Monday session on Wall Street, TransCode Therapeutics (NASDAQ: RNAZ) saw its shares drive up 300% ... TransCode Therapeutics Withdraws Public Offering (GlobeNewswire) +10.36% Oct-27-23 08:16AM Why Is TransCode Therapeutics (RNAZ) Stock Down 25% Today? (InvestorPlace) -21.61% 08:00AM Nasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on The Nasdaq Stock Market Subject to ConditionsTranscode Therapeutics Inc RNAZ shares are trading lower by 69% to $0.79 Tuesday morning after the company priced its $8 million public offering of 15.7 million shares at $0.51 per share.TransCode Therapeutics ( NASDAQ: RNAZ) said that it has entered into a definitive securities purchase agreement for the purchase and sale of 5,000,000 shares …TransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules Read full article TransCode Therapeutics, Inc.Transcode therapeutics, inc. Has entered into a definitive securities purchase agreement for the purchase and sale of 5,000,000 shares of common stock. The company is an rna oncology company committed to more effectively treating cancer using rna therapeutics. The gross proceeds from the offering are expected to be approximately $1.2 million.BOSTON, Sept. 25, 2023 (GLOBE NEWSWIRE) -- TransCode TheItem 1. Description of Registrant’s Securities to be Registered. For TransCode Therapeutics hasn’t yet revealed details of the proposed public stock offering. RNAZ Trading at -49.61% from the 50-Day Moving Average After a stumble in the market that brought RNAZ to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.06% of loss for the given period.TransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business Update 11-14 . Nasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on The Nasdaq Stock Market Subject to Conditions 10-27 - 2 views . TransCode Therapeutics Announces Preliminary Clinical Results in First Patient in Phase 0 Clinical … Therapeutic counseling is a psychological service that TransCode Therapeutics, Inc. (Nasdaq: RNAZ) has closed a registered direct offering, selling 5,000,000 shares of common stock at $0.242 per share, resulting in gross proceeds of $1.2 million. The company plans to use the net proceeds for clinical trials with its lead therapeutic candidate, TTX-MC138, and for general corporate purposes. TransCode Therapeutics (NASDAQ: RNAZ) stock is ral

Certain Stock Options of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 24-NOV-2023. Nov. 23: CI TransCode Therapeutics, Inc. …9 thg 6, 2023 ... (Nasdaq: RNAZ) on its registered direct offering of an aggregate of 2,000,000 shares of its common stock, together with accompanying common ...BOSTON, Dec. 04, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ) (the "Company"), an RNA oncology company committed to …First Quarter 2022 Financial Highlights. Cash and cash equivalents were $16.9 million at March 31, 2022, compared to $20.8 million at December 31, 2021. Research and development expense was $1.9 ...

Latest Filings (excluding insider transactions) · 3.01 - Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ...BOSTON, Dec. 04, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company …Certain Stock Options of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 24-NOV-2023. Nov. 23: CI TransCode Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 Nov. 14: CI …

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. According to the U.S. Food and Drug Administration (FDA), a d. Possible cause: Get the latest Galera Therapeutics Inc (GRTX) real-time quote, historical performa.